(E)-N-[2-(2-Methylphenyl)ethyl]morpholine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-[2-(2-Methylphenyl)ethyl]morpholine
• 英文别名: 4-(2-methylphenethyl)morpholine；4-[2-(2-Methylphenyl)ethyl]morpholine
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: TYWJEDNKJMMOFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-甲基苯乙醛 在 三(五氟苯基)硼烷 、 频那醇硼烷 作用下， 以 氯仿 、 1,2-二氯乙烷 为溶剂， 反应 11.0h， 生成 (E)-N-[2-(2-Methylphenyl)ethyl]morpholine
  参考文献：
  名称：

  B（C6F5）3-催化的串联质子化/氘代和原位形成的烯胺还原

  摘要：

  开发了一种高效的B（C 6 F 5）3催化串联质子化/氘代和在水和频哪醇硼烷存在下还原原位形成的烯胺的方法。叔胺的区域选择性β-氘化具有高的化学和区域选择性。D 2 O被用作一种容易获得且廉价的氘源。机理研究表明，B（C 6 F 5）3可以活化水以促进烯胺的质子化和还原。

  DOI：

  10.1039/d1ob00316j

文献信息

• Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
  申请人：Bonfanti Jean-Francois

  公开号：US20070099924A1

  公开（公告）日：2007-05-03

  Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof, wherein G is a direct bond or C 1-10 alkanediyl optionally substituted with one or more hydroxy, C 1-6 alkyloxy, Ar 1 C 1-6 alkyloxy, C 1-6 alkylthio, Ar 1 C 1-6 alkylthio, HO(—CH 2 —CH 2 —O) n —, C 1-6 alkyloxy(—CH 2 —CH 2 —O) n — or Ar 1 C 1-6 alkyloxy(—CH 2 —CH 2 —O) n —; R 1 is Ar 1 or a monocyclic or bicyclic heterocycle; Q is hydrogen, amino or mono- or di(C 1-4 alkyl)amino; one of R 2a and R 3a is selected from halo, optionally mono- or polysubstituted C 1-6 alkyl, optionally mono- or polysubstituted C 2-6 alkenyl, nitro, hydroxy, Ar 2 , N(R 4a R 4b ), N(R 4a R 4b )sulfonyl, N(R 4a R 4b )carbonyl, C 1-6 alkyloxy, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, or —C(═Z)Ar 2 ; and the other one of R 2a and R 3a is hydrogen; in case R 2a is different from hydrogen then R 2b is hydrogen, C 1-6 alkyl or halogen and R 3b is hydrogen; in case R 3a is different from hydrogen then R 3b is hydrogen, C 1-6 alkyl or halogen and R 2b is hydrogen. Compositions containg these compounds as active ingredient and processes for preparing these compounds and compositions.

  具有RSV复制抑制活性的氨基苯并咪唑和苯并咪唑，其具有以下公式的前药，N-氧化物，加成盐，季铵盐，金属配合物和立体化学异构体形式，其中G是直接键或C1-10烷二基，可选地取代一个或多个羟基，C1-6烷氧基，Ar1C1-6烷氧基，C1-6烷基硫基，Ar1C1-6烷基硫基，HO（-CH2-CH2-O）n-，C1-6烷氧基（-CH2-CH2-O）n-或Ar1C1-6烷氧基（-CH2-CH2-O）n-; R1是Ar1或单环或双环杂环; Q是氢，氨基或单或双（C1-4烷基）氨基之一; R2a和R3a中的一个选自卤素，可选择单或多取代的C1-6烷基，可选择单或多取代的C2-6烯基，硝基，羟基，Ar2，N（R4aR4b），N（R4aR4b）磺酰基，N（R4aR4b）羰基，C1-6烷氧基，Ar2氧基，Ar2C1-6烷氧基，羧基，C1-6烷氧羰基或-C（═Z）Ar2; R2a和R3a中的另一个是氢; 在R2a不同于氢的情况下，R2b是氢，C1-6烷基或卤素，而R3b是氢; 在R3a不同于氢的情况下，R3b是氢，C1-6烷基或卤素，而R2b是氢。含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的过程。
• The First Rhodium-Catalyzed Anti-Markovnikov Hydroamination: Studies on Hydroamination and Oxidative Amination of Aromatic Olefins
  作者：M. Beller、H. Trauthwein、M. Eichberger、C. Breindl、J. Herwig、T. E. Müller、O. R. Thiel

  DOI：10.1002/(sici)1521-3765(19990401)5:4<1306::aid-chem1306>3.0.co;2-4

  日期：1999.4.1

  The first transition-metal-catalyzed regiospecific anti-Markovnikov hydroamination of aromatic olefins is reported. Styrene and substituted styrenes react with secondary aliphatic amines, especially morpholine and N-arylpiperazines, in the presence of cationic rhodium complexes to give 2-aminoethenylbenzene and 2-aminoethylbenzene derivatives. Cationic [Rh(cod)(2)]+BF4- and various phosphines (1:2-mixture) were employed as in situ catalysts. According to labeling experiments, there is no evidence that the hydroamination is a consecutive hydrogenation of a previously formed enamine. Hydroamination with simple secondary amines, for example piperidine, can also be achieved by the use of a higher olefin concentration and higher reaction temperatures than those given in previously published reaction procedures. Kinetic investigations of the major reaction pathway reveal that the reaction rate of the oxidative amination and the hydroamination is dependent on the styrene and on the catalyst concentration, and independent of the amine concentration. Experiments that employed deuterium-labeled amines (N-D) provided evidence that the mechanism involves an amine-activating pathway, The substituents on the styrene, the phosphine ligand, and the solvent influence the yield of the aminations and the enamine:alkylamine ratio.
• COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS
  申请人：ALIOS BIOPHARMA, INC.

  公开号：US20160045528A1

  公开（公告）日：2016-02-18

  Disclosed herein are a combination of compounds and methods of using the combination of compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.
• US8044073B2
  申请人：——

  公开号：US8044073B2

  公开（公告）日：2011-10-25
• [EN] A NOVEL PROCESS FOR THE PREPARATION OF CRYSTALLINE LINEZOLID FORM-III<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE LINÉZOLIDE CRISTALLIN DE FORME III
  申请人：LEE PHARMA LTD

  公开号：WO2018051360A1

  公开（公告）日：2018-03-22

  The invention relates to a novel process for preparation of crystalline Linezolid Form-III. The crystalline Linezolid Form-III obtained by the process is highly pure with HPLC purity equal to or greater than 99.9% with single un-known impurity less than 0.05%.